These Drug Makers Are Still Standing Strong

In 2007 Pfizer (PFE) formed a partnership with Bristol-Myers Squibb (BMY) to develop the anti-coagulant drug "Eliquis" that reduces blood clotting. In this partnership, Pfizer and Bristol-Myers share the profits 60:40 respectively. The FDA approved this drug in late 2012 and both companies are now moving ahead to develop supplements to treat patients more effectively.

After receiving approval for Eliquis, Pfizer and Bristol-Myers Squibb also received approval from the FDA for its supplemental New Drug Application, or sNDA, in July 2013. A sNDA is an application that enables the company to innovate or make changes in a drug that has already been approved. Eliquis is used to treat venous thromboembolism, or VTE, patients and reduces the probability of deep vein thrombosis, or DVT, a blood clot in veins.Read more